NCT05486013View on ClinicalTrials.gov

Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

May 26, 2025

Study Completion Date

November 26, 2025

Conditions
Mantle Cell Lymphoma
Trial Locations (1)

100083

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Hospital

OTHER_GOV

collaborator

Peking Union Medical College Hospital

OTHER

collaborator

Beijing Tsinghua Changgeng Hospital

OTHER

collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Chinese PLA General Hospital

OTHER

lead

Peking University Third Hospital

OTHER